Novel tumor derived peptides in vaccines

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

Abstract

Traditionally, cancer vaccines have consisted of recombinant antigens or tumor cell lysates. Whole tumor-derived preparations contain predominantly normal self-proteins of no therapeutic benefit or material with the potential to induce further malignancy. Thus, the identification and administration of tumor-specific antigens rather than crude tumor preparations are desirable. The most precise selection of vaccine components exists in epitope-based peptide vaccines, which represent the minimal immunogenic region of an antigen and allow exquisite control of immune responses. The difficulties associated with peptide-based vaccines; including stability, delivery, and the diversity of human immunogenetics have now mostly been overcome by high throughput sequencing of haplotype- specific peptide ligands and the ability to modify peptides to enhance both their immunogenicity and stability. Such recent progress makes it very probable that peptide-based cancer vaccines will enter the human therapeutics marketplace in the near future.
Original languageEnglish
Title of host publicationHandbook of Biologically Active Peptides
EditorsAbba J Kastin
Place of PublicationUSA
PublisherElsevier
Pages580 - 589
Number of pages10
Edition2nd
ISBN (Print)9780123850959
DOIs
Publication statusPublished - 2013

Cite this

Purcell, A. W., Croft, N. P., & Dudek, N. L. (2013). Novel tumor derived peptides in vaccines. In A. J. Kastin (Ed.), Handbook of Biologically Active Peptides (2nd ed., pp. 580 - 589). USA: Elsevier. https://doi.org/10.1016/B978-0-12-385095-9.00079-8
Purcell, Anthony Wayne ; Croft, Nathan Paul ; Dudek, Nadine Lee. / Novel tumor derived peptides in vaccines. Handbook of Biologically Active Peptides. editor / Abba J Kastin. 2nd. ed. USA : Elsevier, 2013. pp. 580 - 589
@inbook{b91f79cb032440989815142f358a425d,
title = "Novel tumor derived peptides in vaccines",
abstract = "Traditionally, cancer vaccines have consisted of recombinant antigens or tumor cell lysates. Whole tumor-derived preparations contain predominantly normal self-proteins of no therapeutic benefit or material with the potential to induce further malignancy. Thus, the identification and administration of tumor-specific antigens rather than crude tumor preparations are desirable. The most precise selection of vaccine components exists in epitope-based peptide vaccines, which represent the minimal immunogenic region of an antigen and allow exquisite control of immune responses. The difficulties associated with peptide-based vaccines; including stability, delivery, and the diversity of human immunogenetics have now mostly been overcome by high throughput sequencing of haplotype- specific peptide ligands and the ability to modify peptides to enhance both their immunogenicity and stability. Such recent progress makes it very probable that peptide-based cancer vaccines will enter the human therapeutics marketplace in the near future.",
author = "Purcell, {Anthony Wayne} and Croft, {Nathan Paul} and Dudek, {Nadine Lee}",
year = "2013",
doi = "10.1016/B978-0-12-385095-9.00079-8",
language = "English",
isbn = "9780123850959",
pages = "580 -- 589",
editor = "Kastin, {Abba J}",
booktitle = "Handbook of Biologically Active Peptides",
publisher = "Elsevier",
address = "Netherlands",
edition = "2nd",

}

Purcell, AW, Croft, NP & Dudek, NL 2013, Novel tumor derived peptides in vaccines. in AJ Kastin (ed.), Handbook of Biologically Active Peptides. 2nd edn, Elsevier, USA, pp. 580 - 589. https://doi.org/10.1016/B978-0-12-385095-9.00079-8

Novel tumor derived peptides in vaccines. / Purcell, Anthony Wayne; Croft, Nathan Paul; Dudek, Nadine Lee.

Handbook of Biologically Active Peptides. ed. / Abba J Kastin. 2nd. ed. USA : Elsevier, 2013. p. 580 - 589.

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

TY - CHAP

T1 - Novel tumor derived peptides in vaccines

AU - Purcell, Anthony Wayne

AU - Croft, Nathan Paul

AU - Dudek, Nadine Lee

PY - 2013

Y1 - 2013

N2 - Traditionally, cancer vaccines have consisted of recombinant antigens or tumor cell lysates. Whole tumor-derived preparations contain predominantly normal self-proteins of no therapeutic benefit or material with the potential to induce further malignancy. Thus, the identification and administration of tumor-specific antigens rather than crude tumor preparations are desirable. The most precise selection of vaccine components exists in epitope-based peptide vaccines, which represent the minimal immunogenic region of an antigen and allow exquisite control of immune responses. The difficulties associated with peptide-based vaccines; including stability, delivery, and the diversity of human immunogenetics have now mostly been overcome by high throughput sequencing of haplotype- specific peptide ligands and the ability to modify peptides to enhance both their immunogenicity and stability. Such recent progress makes it very probable that peptide-based cancer vaccines will enter the human therapeutics marketplace in the near future.

AB - Traditionally, cancer vaccines have consisted of recombinant antigens or tumor cell lysates. Whole tumor-derived preparations contain predominantly normal self-proteins of no therapeutic benefit or material with the potential to induce further malignancy. Thus, the identification and administration of tumor-specific antigens rather than crude tumor preparations are desirable. The most precise selection of vaccine components exists in epitope-based peptide vaccines, which represent the minimal immunogenic region of an antigen and allow exquisite control of immune responses. The difficulties associated with peptide-based vaccines; including stability, delivery, and the diversity of human immunogenetics have now mostly been overcome by high throughput sequencing of haplotype- specific peptide ligands and the ability to modify peptides to enhance both their immunogenicity and stability. Such recent progress makes it very probable that peptide-based cancer vaccines will enter the human therapeutics marketplace in the near future.

UR - http://www.sciencedirect.com/science/book/9780123850959#ancs8

U2 - 10.1016/B978-0-12-385095-9.00079-8

DO - 10.1016/B978-0-12-385095-9.00079-8

M3 - Chapter (Book)

SN - 9780123850959

SP - 580

EP - 589

BT - Handbook of Biologically Active Peptides

A2 - Kastin, Abba J

PB - Elsevier

CY - USA

ER -

Purcell AW, Croft NP, Dudek NL. Novel tumor derived peptides in vaccines. In Kastin AJ, editor, Handbook of Biologically Active Peptides. 2nd ed. USA: Elsevier. 2013. p. 580 - 589 https://doi.org/10.1016/B978-0-12-385095-9.00079-8